Amicus Therapeutics is a biotechnology company that focuses on researching treatment for rare and orphan diseases. Although the company is based in Cranbury, New Jersey, they operate a second research site in San Diego, California. Amicus was founded in 2002 but didn’t go public until 2007. The company is fairly small, with around five hundred employees. Amicus is primarily research based and has to have other companies take care of manufacturing. Although the company offers no products as of 2017, a few potential products are in the final stages of being approved for commercial use.
Fabry Disease is one illness that Amicus Therapeutics is currently researching. The company has developed two potential products to help treat it: Galafold/Migalastat Monotherapy and novel ERTs (Enzyme Replacement Therapy). Galafold is an orally administered monotherapy that has full approval in Europe and is ready to be released to the public. Migalastat Monotherapy and Galafold are one in the same, with Galafold being the brand name. While the product is ready for use in Europe, it is still in the approval stages in the Americas and the rest of the world. Amicus’ ERTs for Fabry Disease are in preclinical stages of research.
In addition to Fabry Disease, Amicus Therapeutics studies two other illnesses specifically, Pompe Disease and Epidermolysis Bullosa. Their product for Pompe Disease, a novel ERT named ATB200 and AT2221 are in the middle of the final phase of testing. This treatment will require a chaperone as well. Amicus’ medication for Epidermolysis Bullosa is named SD-101. It is a topical medication. Currently, SD-101 is in the third and final phase of testing.
While Amicus Therapeutics focuses on a few diseases specifically, they also conduct research on other rare diseases and plan treatments for patients with these illnesses. Most of their medications for these various diseases are novel ERTs and most of them are in the primary research phase of development.
Dedicated to research and creating treatments for those with rare illnesses, Amicus Therapeutics is a company to keep an eye on. Several products are nearing their final stages and are one step closer to helping others survive.
More here: Crunchbase
Whitney Wolfe is the CEO of Bumble, and she has created an atmosphere around the company that the public enjoys. This article explains how the company is offering the best services to women who wish to date, and they are growing every day in new and interesting ways.
Whitney Wolfe is one of the best tech executives in the world, and she is showing why she has been lauded for her work many times over.
#1: Bumble Is Growing
Bumble is growing with the Bumble BFF app that will help women make friends in the same way they have dated. The person who has downloaded the app may use it to make friends, and they will find that there are a number of different people who may have the same interests as them.
#2: The Dating App
The dating app gives women quite a lot of control because they decide which men they want to talk to. They will notice how simple it is to keep away any man who would harass them, and they will give men a chance to talk only if they have been vetted. Whitney Wolfe created this app to ensure that women would feel safe, and she has grown the app with the safety marketing angle.
#3: Her Leadership
Whitney Wolfe has led the company for many years, and she is helping it grow to ensure that the women who want to date in a better way will feel the freedom that comes with this app. The app is easy for women to put on their phones, and the app is easier for women to use when they want to meet men in a better environment.
The Bumble has become a worldwide name that everyone knows or wants to try. The app has grown from its origins to help all women Date safely, and they are coming out with an app that will help women make friends. The woman who wishes to have a much better time making friends will notice how simple it is to start this new app to find new friends in their area.
Follow Whitney Wolfe on Instagram.
Background and Education
Based in Scottsdale, Arizona, Jason Hope is an excellent entrepreneur. Technology fascinates Jason vastly, which has made him formulate hypotheses on how life will be in the future; hence he is a renowned futurist. Also, Jason is a committed philanthropist, regularly donating towards charitable causes.
Jason received his tertiary education from the Arizona State University. He graduated with both a Bachelor’s degree in Finance and an MBA from the renowned institution.
Jason’s obsessions with technology trends have honed him into one of the most esteemed futurists in the industry. He uses his nous on the subject to avail advice to individuals and corporate institutions who are willing to stay relevant by evolving their methods to match current technology.
The Internet of Things (IoT) particularly impresses Jason Hope. He is an ardent believer of this discovery, hoping that it will be possible to synchronize all electronics in the coming days. Jason thinks that IoT is a potential game changer, should developers be able to harness its maximum capabilities.
Jason Hope envisions a future world where devices will be able to communicate to each other seamlessly. As more corporate institutions continue to embrace this invention, the more IoT compliant appliances will be made available in the market. Jason predicts that there will come a time where it will be mandatory to have compliant devices, lest you get left behind.
As good as he a tech hobbyist, Jason also has a benevolent side. This is demonstrated through his constant giving to humanitarian causes.
One of the most noteworthy donations was the $500,000 granted to the SENS Foundation. The foundation conducts research with the aim of fighting aging and conditions that come as a consequence of old age. Being a technology fan, Jason was inspired by the way SENS incorporated tech into their research, which further motivated him to grant the donation.
Follow on Jason Hope on Twitter.